Akebia Therapeutics (AKBA) Cash from Investing Activities (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Cash from Investing Activities of -$62000.0 for Q1 2026, down 140.26% year-over-year from $154000.0 in Q1 2025, and up 99.21% quarter-over-quarter from -$7.9 million in Q4 2025.
Akebia Therapeutics (AKBA) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Cash from Investing Activities for 13 consecutive years, with -$62000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 140.26% year-over-year to -$62000.0; the TTM figure through Mar 2026 stood at -$8.1 million (down 6828.93% YoY), while the FY2025 annual figure was -$7.9 million, down 23918.18% from the prior year.
- Cash from Investing Activities improved to -$62000.0 in Q1 2026 per AKBA's latest filing, from -$7.9 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $154000.0 in Q1 2025 and bottomed at -$7.9 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$903888.9 across 4 years, with a median of -$62000.0 in 2026.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 100.57% — and 2025, when it tumbled 393750.0%.
- Akebia Therapeutics' Cash from Investing Activities stood at -$114000.0 in 2022, then jumped by 98.25% to -$2000.0 in 2024, then sank by 393750.0% to -$7.9 million in 2025, then surged by 99.21% to -$62000.0 in 2026.
- Business Quant data shows AKBA's Cash from Investing Activities at -$62000.0 in Q1 2026, -$7.9 million in Q4 2025, and -$77000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.08 Mn |
| Jun 30, 2026 | -4.08 Mn |
| Mar 31, 2026 | -62,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -7.88 Mn |
| Dec 31, 2025 | -7.88 Mn |
| Sep 30, 2025 | -77,000.00 |
| Sep 30, 2025 | -77,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Jun 30, 2025 | -126,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Mar 31, 2025 | 154,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Mar 31, 2022 | -114,000.00 |
| Mar 31, 2022 | -114,000.00 |